S
Sera Economics
← US Companies

ASTRAZENECA PLC

AZN · NYSE · CIK 0000901832

SIC 2834

Pharmaceutical Preparations

Category

Chemicals

Entity

other

Incorp.

X0

Fiscal Y/E

1231

Source: SEC EDGAR · All filings on SEC →

Investment Indicators

$181.86

-0.99 (-0.54%)

Open

$183.79

High

$185.81

Low

$181.73

Prev Close

$182.85

Volume

2,012,059

52W High

$210.50

52W Low

$130.04

50-day MA

$193.82

Quote as of: 2026-05-11

Market Cap

$283.47B

P/E

27.54

P/B

5.99

PEG

1.52

EPS

6.64

BPS

30.56

Dividend Yield

1.75%

Beta

0.22

Financial Statements

No XBRL data — applies to ETFs and some funds

📄 SEC Filings

6-K

Foreign Current

TOTAL VOTING RIGHTS AND ADMISSION OF SHARES

2026-05-01

Open →

6-K

Foreign Current

FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER

2026-05-01

Open →

6-K

Foreign Current

FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER

2026-05-01

Open →

6-K

Foreign Current

1ST QUARTER RESULTS

2026-04-29

Open →

6-K

Foreign Current

BREZTRI APPROVED IN THE US FOR ASTHMA

2026-04-28

Open →

6-K

Foreign Current

SAPHNELO SELF-ADMINISTRATION APPROVED IN THE US

2026-04-27

Open →

6-K

Foreign Current

DIRECTORATE CHANGE

2026-04-23

Open →

6-K

Foreign Current

I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINT

2026-04-21

Open →

6-K

Foreign Current

THIRD TOZORAKIMAB POSITIVE PHASE III IN COPD

2026-04-20

Open →

6-K

Foreign Current

RESULT OF AGM

2026-04-09

Open →

6-K

Foreign Current

IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER

2026-04-02

Open →

6-K

Foreign Current

TOTAL VOTING RIGHTS AND ADMISSION OF SHARES

2026-04-01

Open →

6-K

Foreign Current

EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS

2026-03-31

Open →

6-K

Foreign Current

TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS

2026-03-27

Open →

6-K

Foreign Current

NOTIFICATION OF ADMISSION OF SHARES

2026-03-20

Open →

6-K

Foreign Current

IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER

2026-03-16

Open →

6-K

Foreign Current

NOTICE OF AGM

2026-03-10

Open →

6-K

Foreign Current

FORM 6-K

2026-03-10

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-03-06

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-03-06

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2026-03-06

Open →

6-K

Foreign Current

FORM 6-K

2026-03-02

Open →

6-K

Foreign Current

TOTAL VOTING RIGHTS

2026-03-02

Open →

6-K

Foreign Current

ASTRAZENECA PRICES A $2BN BOND OFFERING

2026-02-26

Open →

6-K

Foreign Current

FILING OF FORM 20-F WITH SEC

2026-02-25

Open →

20-F

Foreign Annual

20-F

2026-02-24

Open →

6-K

Foreign Current

FORM 6-K

2026-02-24

Open →

6-K

Foreign Current

ANNUAL FINANCIAL REPORT

2026-02-24

Open →

6-K

Foreign Current

DIRECTORATE CHANGE

2026-02-24

Open →

6-K

Foreign Current

FIXED-DURATION CALQUENCE COMBO APPROVED IN US

2026-02-20

Open →

6-K

Foreign Current

FINAL RESULTS

2026-02-10

Open →

6-K

Foreign Current

UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION

2026-02-03

Open →

6-K

Foreign Current

TOTAL VOTING RIGHTS

2026-02-02

Open →

6-K

Foreign Current

IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER

2026-02-02

Open →

6-K

Foreign Current

ASTRAZENECA BEGINS TRADING ON NYSE

2026-02-02

Open →

6-K

Foreign Current

ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC

2026-01-30

Open →

6-K

Foreign Current

ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030

2026-01-29

Open →

6-K

Foreign Current

ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE

2026-01-20

Open →

6-K

Foreign Current

AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON

2026-01-08

Open →

6-K

Foreign Current

TOTAL VOTING RIGHTS

2026-01-02

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2025-12-22

Open →

6-K

Foreign Current

ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC

2025-12-22

Open →

6-K

Foreign Current

UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB

2025-12-22

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2025-12-19

Open →

6-K

Foreign Current

SUBCUTANEOUS SAPHNELO APPROVED IN EU

2025-12-16

Open →

6-K

Foreign Current

ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC

2025-12-16

Open →

6-K

Foreign Current

HOLDING(S) IN COMPANY

2025-12-04

Open →

6-K

Foreign Current

BLOCK LISTING INTERIM REVIEW

2025-12-01

Open →

6-K

Foreign Current

TOTAL VOTING RIGHTS

2025-12-01

Open →

6-K

Foreign Current

IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER

2025-11-26

Open →

6-K

Foreign Current

ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND

2025-11-24

Open →

6-K

Foreign Current

KOSELUGO (SELUMETINIB) APPROVED IN THE US

2025-11-20

Open →

6-K

Foreign Current

HOLDING(S) IN COMPANY

2025-11-17

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2025-11-14

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2025-11-10

Open →

6-K

Foreign Current

9M AND Q3 2025 RESULTS

2025-11-06

Open →

6-K

Foreign Current

RESULT OF GENERAL MEETING

2025-11-03

Open →

6-K

Foreign Current

TOTAL VOTING RIGHTS

2025-11-03

Open →

6-K

Foreign Current

FORM 6-K

2025-11-03

Open →

6-K

Foreign Current

DIRECTOR DECLARATION

2025-10-28

Open →

6-K

Foreign Current

KOSELUGO (SELUMETINIB) APPROVED IN THE EU

2025-10-28

Open →

6-K

Foreign Current

TEZSPIRE APPROVED IN EU FOR CRSWNP

2025-10-22

Open →

6-K

Foreign Current

US FDA APPROVES TEZSPIRE IN CRSWNP

2025-10-20

Open →

6-K

Foreign Current

POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO

2025-10-20

Open →

6-K

Foreign Current

AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES

2025-10-14

Open →

6-K

Foreign Current

BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL

2025-10-07

Open →

6-K

Foreign Current

DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02

2025-10-06

Open →

6-K

Foreign Current

TOTAL VOTING RIGHTS

2025-10-01

Open →

6-K

Foreign Current

ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05

2025-09-29

Open →

6-K

Foreign Current

AZN HARMONISES LISTING STRUCTURE

2025-09-29

Open →

6-K

Foreign Current

6-K

2025-09-29

Open →

6-K

Foreign Current

DIRECTOR/PDMR SHAREHOLDING

2025-09-25

Open →

6-K

Foreign Current

KOSELUGO RECOMMENDED FOR EU APPROVAL

2025-09-22

Open →

6-K

Foreign Current

TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP

2025-09-22

Open →

6-K

Foreign Current

SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC

2025-09-17

Open →

6-K

Foreign Current

UPDATE ON RESOLUTE PHASE III TRIAL

2025-09-17

Open →

6-K

Foreign Current

TOTAL VOTING RIGHTS

2025-09-02

Open →

6-K

Foreign Current

HOLDING(S) IN COMPANY

2025-08-28

Open →

6-K

Foreign Current

HOLDING(S) IN COMPANY

2025-08-26

Open →

6-K

Foreign Current

HOLDING(S) IN COMPANY

2025-08-21

Open →

Other filings (20)
ASTRAZENECA PLC (AZN) — Pharmaceutical Preparations | Sera Economics